Budding yeast greatwall and endosulfines control activity and spatial regulation of PP2A(Cdc55) for timely mitotic

Maria Angeles Juanes1, Rita Khoueiry, Thomas Kupka

  • 1Centre de Recherche en Biochimie Macromoléculaire, Montpellier, France.

Plos Genetics
|July 18, 2013
PubMed

Insights

Budding yeast endosulfines (Igo1, Igo2) regulate entry into mitosis by interacting with PP2A(Cdc55) phosphatase. This conserved module, involving Greatwall kinase, adapts to different organisms

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Mitotic entry is controlled by cyclinB/Cdk1 activity, regulated by feedback loops.
  • Greatwall kinase phosphorylates endosulfines, inhibiting PP2A-B55 phosphatase to promote mitosis.
  • Budding yeast utilizes Cdc14 as the main Cdk1 antagonist, with PP2A(Cdc55) promoting mitosis.

Purpose of the Study:

  • To investigate the role of budding yeast endosulfines (Igo1, Igo2) in mitotic regulation.
  • To determine if yeast endosulfines possess conserved PP2A-binding and inhibitory activities.
  • To elucidate the conserved regulatory module of Greatwall, endosulfines, and PP2A in mitosis.

Main Methods:

  • Investigated cell cycle-regulated binding of Igo1/Igo2 to PP2A(Cdc55) upon Rim15 phosphorylation.
  • Assessed inhibitory activity of phosphorylated Igo1 on PP2A(Cdc55) in vitro and in Xenopus egg extracts.
  • Analyzed the effect of IGO1/IGO2 deletion on PP2A activity and mitotic entry under temperature stress.

Main Results:

  • Yeast endosulfines (Igo1, Igo2) bind PP2A(Cdc55) in a cell cycle-dependent manner.
  • Phosphorylated Igo1 inhibits PP2A(Cdc55) and promotes mitotic entry, showing conserved activity.
  • Endosulfines also positively regulate PP2A activity in yeast and contribute to nuclear export of PP2A(Cdc55).

Conclusions:

  • Igo proteins are integral to the positive feedback loop activating Cdk1 in budding yeast.
  • Greatwall, endosulfines, and PP2A form a conserved regulatory module for mitosis.
  • This module is adaptable, accommodating variations in mitotic entry control across species.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

No description available
4.3K
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
539